Synchronous two-nodule hepatocellular carcinoma without satellite nodules is associated with better survival outcomes compared with satellite-nodule hepatocellular carcinoma.
2/5 보강
TL;DR
Synchronous two-nodule HCC without satellite nodules represents a prognostically favourable subgroup distinct from satellite-nodule HCC, and a simplified morphology-based stratification may better reflect clinical outcomes in multifocal HCC.
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
153 patients with synchronous multifocal HCC who underwent surgical resection, including cases with two discrete nodules, more than two nodules and satellite nodules.
I · Intervention 중재 / 시술
surgical resection, including cases with two discrete nodules, more than two nodules and satellite nodules
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Synchronous two-nodule HCC without satellite nodules represents a prognostically favourable subgroup distinct from satellite-nodule HCC. A simplified morphology-based stratification may better reflect clinical outcomes in multifocal HCC.
OpenAlex 토픽 ·
Hepatocellular Carcinoma Treatment and Prognosis
Cholangiocarcinoma and Gallbladder Cancer Studies
Multiple and Secondary Primary Cancers
Synchronous two-nodule HCC without satellite nodules represents a prognostically favourable subgroup distinct from satellite-nodule HCC, and a simplified morphology-based stratification may better ref
APA
Yu-Han Wu, Yu-Fen Tseng, et al. (2026). Synchronous two-nodule hepatocellular carcinoma without satellite nodules is associated with better survival outcomes compared with satellite-nodule hepatocellular carcinoma.. Journal of clinical pathology, 79(5), 332-339. https://doi.org/10.1136/jcp-2025-210607
MLA
Yu-Han Wu, et al.. "Synchronous two-nodule hepatocellular carcinoma without satellite nodules is associated with better survival outcomes compared with satellite-nodule hepatocellular carcinoma.." Journal of clinical pathology, vol. 79, no. 5, 2026, pp. 332-339.
PMID
41708315 ↗
Abstract 한글 요약
[AIMS] Multifocal hepatocellular carcinoma (HCC) is traditionally classified as multicentric occurrence (MO) or intrahepatic metastasis, a distinction that is difficult to apply in routine practice and not reflected in current staging systems. We aimed to assess the prognostic significance of different multifocal HCC patterns using simple, clinically applicable criteria.
[METHODS] We retrospectively analysed 153 patients with synchronous multifocal HCC who underwent surgical resection, including cases with two discrete nodules, more than two nodules and satellite nodules. 76 patients with solitary HCC served as controls. Histological classification based on Liver Cancer Study Group of Japan criteria was supplemented with promoter mutation analysis in selected cases. Overall survival (OS) and recurrence-free survival (RFS) were evaluated using Kaplan-Meier and Cox regression analyses.
[RESULTS] Histologic criteria alone failed to classify a substantial proportion of two-nodule HCCs. Although promoter analysis allowed partial reclassification, patients with undetermined two-nodule HCC had survival outcomes comparable to those classified as MO. In contrast, HCCs with satellite nodules showed significantly poorer OS and RFS. Multivariate analysis identified microvascular invasion and the presence of satellite nodules-but not two-nodule multifocality-as independent adverse prognostic factors. Notably, patients with two discrete nodules without satellite lesions did not show a statistically significant difference in OS or RFS compared with those with solitary HCC.
[CONCLUSIONS] Synchronous two-nodule HCC without satellite nodules represents a prognostically favourable subgroup distinct from satellite-nodule HCC. A simplified morphology-based stratification may better reflect clinical outcomes in multifocal HCC.
[METHODS] We retrospectively analysed 153 patients with synchronous multifocal HCC who underwent surgical resection, including cases with two discrete nodules, more than two nodules and satellite nodules. 76 patients with solitary HCC served as controls. Histological classification based on Liver Cancer Study Group of Japan criteria was supplemented with promoter mutation analysis in selected cases. Overall survival (OS) and recurrence-free survival (RFS) were evaluated using Kaplan-Meier and Cox regression analyses.
[RESULTS] Histologic criteria alone failed to classify a substantial proportion of two-nodule HCCs. Although promoter analysis allowed partial reclassification, patients with undetermined two-nodule HCC had survival outcomes comparable to those classified as MO. In contrast, HCCs with satellite nodules showed significantly poorer OS and RFS. Multivariate analysis identified microvascular invasion and the presence of satellite nodules-but not two-nodule multifocality-as independent adverse prognostic factors. Notably, patients with two discrete nodules without satellite lesions did not show a statistically significant difference in OS or RFS compared with those with solitary HCC.
[CONCLUSIONS] Synchronous two-nodule HCC without satellite nodules represents a prognostically favourable subgroup distinct from satellite-nodule HCC. A simplified morphology-based stratification may better reflect clinical outcomes in multifocal HCC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.